REGN
REGENERON PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$784.85
−0.58%Next report
Analyst consensus
- Next report date
- Oct 28, 2026
- EPS estimate
- $16
- Revenue estimate
- $4.5B
Latest reported
- Last report date
- Jul 30, 2026
- EPS actual
- $14
- EPS estimate
- $10
- Revenue actual
- $4.3B
- Revenue estimate
- $3.8B
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 11
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +26.6%
- Revenue beats (12Q)
- 11
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $760
- PT range
- $185 – $1.0K
- Analysts
- 11
6 Buy5 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Jul 30, 2026 | $10 | $14 | Beat 40.65% | $4.3B |
| Apr 29, 2026 | $8.91 | $9.47 | Beat 6.29% | $3.6B |
| Jan 30, 2026 | $11 | $11 | Beat 6.52% | $3.9B |
| Aug 1, 2025 | $8.43 | $13 | Beat 52.91% | $3.7B |
| Feb 4, 2025 | $11 | $12 | Beat 7.50% | $3.8B |
| Oct 31, 2024 | $12 | $12 | Beat 6.58% | $3.7B |
| Aug 1, 2024 | $11 | $12 | Beat 9.05% | $3.5B |
| May 2, 2024 | $10 | $9.55 | Miss -6.14% | $3.1B |
| Feb 2, 2024 | $11 | $12 | Beat 10.49% | $3.4B |
| Nov 2, 2023 | $11 | $12 | Beat 8.46% | $3.4B |
| Aug 3, 2023 | $9.76 | $10 | Beat 4.88% | $3.2B |
| May 4, 2023 | $9.17 | $10 | Beat 10.02% | $3.2B |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 28, 2026